No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T17:57:55.768Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T17:57:55.768Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for PolyPid Ltd. (PYPD) stock was $5.17 as of Oct 6, 2026, 1:54 PM EDT, down 0.58% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +48.3% · 3-year avg +11.5%/yr · 5-year avg -52.7%/yr
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions.
Biotechnology · Petah Tikva, HM
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
0.25
Revenue Est.
$15.00M
Last Quarter Results
EPS
$-0.35
vs Estimate
$-0.38
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PYPD | $98.66M | $5.17 | -0.58% | +48.29% | -52.69% | N/A | N/A |
| 2MIST | $97.30M | $0.78 | +0.27% | -62.89% | -33.18% | N/A | vs PYPD |
| 3CNXU | $97.23M | $3.63 | +16.46% | N/A | N/A | N/A | vs PYPD |
| 4KRRO | $96.95M | $9.74 | -2.31% | -78.27% | -50.72% | N/A | vs PYPD |
| 5JYNT | $102.24M | $7.17 | -0.19% | -20.73% | -40.34% | +11.23% | vs PYPD |
| 6OKUR | $103.06M | $2.54 | -3.23% | -2.94% | -47.19% | N/A | vs PYPD |
N/A
$0.00
vs Estimate
$300000.00
Consensus Rating
Based on 4 analysts
Average Price Target
$11.75
+127.3% upside
Low
$8.00
Current
$5.17
High
$14.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.44 | $-0.40 | $0.65 | 3 |
| Quarter ending Dec 2026 | $-0.47 | $-0.41 | $-0.33 | 3 |
| Quarter ending Mar 2027 | $-0.27 | $-0.27 | $-0.27 | 1 |
| Quarter ending Jun 2027 | $-0.26 | $-0.26 | $-0.26 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.04 | $-1.68 | $-0.31 | 3 |
| FY 2027 | $-1.50 | $-1.23 | $-0.95 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $800000.00 | $800000.00 | $800000.00 | 2 |
| Quarter ending Dec 2026 | $2.30M | $2.30M | $2.30M | 1 |
| Quarter ending Mar 2027 | $1.53M | $1.53M | $1.53M | 1 |
| Quarter ending Jun 2027 | $1.76M | $1.76M | $1.76M | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $666833.00 | $850000.00 | $1.00M | 3 |
| FY 2027 | $3.04M | $8.68M | $14.31M | 3 |
